GENERIC MEDICINES AND HEALTHCARE IN INDIA

Nearly 45% of India’s total healthcare expenditure comes directly from patients’ pockets, which highlights the financial burden of accessing medical treatment in India. When medicine prices become a barrier, patients may delay treatment, skip doses or struggle to complete prescribed courses. Generic medicines offer a practical solution to this crisis by making essential treatments more affordable. 

Generic medicines contain the same active pharmaceutical ingredient as their branded counterparts and are designed to provide the same therapeutic benefits when used appropriately. They have the same strength, dosage form, route of administration and intended medical use. However, they may differ in colour, shape, packaging, taste or coating. These differences do not necessarily affect how the medicine works. Generic medicines generally become available after the original drug’s patent protection expires. Since manufacturers do not have to repeat the initial drug discovery and development process, they can often offer these medicines at significantly lower prices.

Recognising the importance of affordable treatment, the Indian government introduced the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) to improve access to quality generic medicines. The initiative has expanded to more than 19,000 Janaushadhi Kendras across the country, offering medicines at prices generally 50 to 90% lower than comparable branded alternatives. These savings can make a meaningful difference to families managing recurring medical expenses. Generic medicines account for nearly 70% of India’s pharmaceutical market by volume, and have become an important part of the country’s efforts to improve healthcare accessibility. 

The benefits extend beyond lower prices. For people living with chronic conditions such as diabetes, hypertension and heart disease, medication is often a long-term necessity. More affordable medicines can help patients maintain consistent treatment and reduce the likelihood of interruptions caused by financial constraints. Generic medicines can also improve access to essential treatments across both rural and urban areas, while helping healthcare systems use their available resources more efficiently. Their economic impact is evident globally, in the United States alone, generic medicines generated more than US$467 billion savings in  healthcare in 2024.

Despite these advantages, misconceptions about generic medicines persist. A common myth is that lower prices indicate inferior quality or effectiveness. In reality, generic medicines are expected to meet applicable regulatory standards for quality, safety and efficacy. India’s Central Drugs Standard Control Organisation (CDSCO) oversees applicable drug regulatory requirements, while bioequivalence requirements, where applicable, help establish that generic medicines perform comparably to their reference products. Brand loyalty can also influence patient choices, with some people placing greater trust in familiar brand names. Another disadvantage is that certain complex medicines, including some biologics, may not have readily available generic equivalents. Moreover, The quality of generic drugs can vary depending on the manufacturer and the regulatory standards in the country of production. This is particularly relevant in regions with less stringent regulatory oversight, which is why sourcing from GMP certified manufacturers matters.

For India, where affordable treatment remains a significant public health priority, generic medicines represent an opportunity to reduce financial pressure while expanding access to essential medication. Greater public awareness, reliable manufacturing and consistent quality assurance will be crucial to building trust in these alternatives.

Read More

This field is for validation purposes and should be left unchanged.